Related Experiment Video

Updated: Dec 27, 2025

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

10.5K

Challenges and Opportunities for Therapeutic Targeting of Calmodulin Kinase II in Heart

Drew Nassal1, Daniel Gratz1,2, Thomas J Hund1,2,3

  • 1The Frick Center for Heart Failure and Arrhythmia and Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, United States.

Frontiers in Pharmacology
|March 3, 2020
PubMed

Insights

Calcium/calmodulin-dependent protein kinase II (CaMKII) is key in heart failure. Targeting CaMKII offers promise for new therapies, but challenges remain in translating basic science discoveries into effective treatments.

Area of Science:

  • Cardiovascular Research
  • Molecular Cardiology
  • Translational Medicine

Background:

  • Heart failure is a global health challenge with limited therapeutic advancement.
  • Ca2+/calmodulin-dependent protein kinase II (CaMKII) plays a critical role in cardiac maladaptive remodeling and arrhythmias.
  • Existing therapies for heart failure have not kept pace with basic science discoveries.

Purpose of the Study:

  • To review the potential and obstacles in developing CaMKII-targeted therapies for heart failure.
  • To explore strategies for overcoming challenges in translating CaMKII research into clinical applications.
  • To discuss novel approaches for modulating cardiac CaMKII signaling.

Main Methods:

  • Literature review of basic science discoveries and translational efforts.
  • Analysis of small molecule design for CaMKII inhibition.
  • Exploration of alternative targeting strategies, including novel drug delivery and genetic approaches.

Main Results:

  • CaMKII signaling is a promising target for abrogating pathologic cardiac remodeling.
  • Significant barriers exist in translating basic CaMKII research into human therapies.
  • Novel strategies like advanced compound delivery and genetic interventions show potential.

Conclusions:

  • Targeting CaMKII signaling holds significant promise for treating heart failure.
  • Overcoming translational barriers requires innovative approaches in drug design and delivery.
  • Future research should focus on developing and validating these novel strategies for clinical use.
Keywords:
arrhythmiascalmodulin kinase IIcardiac remodelingcardiovascular pharmacologyheart failure

More Related Videos

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter05:04

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter

Published on: February 22, 2022

3.7K
Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

1.6K

Related Concept Videos

Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
5.9K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
365
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
299